Evidence map›Paper›PMID 35409396›Full record

ReviewInternational journal of molecular sciences2022

Sequence Requirements for miR-424-5p Regulating and Function in Cancers.

Jiangying Xuan, Yingxia Liu, Xiaoping Zeng, Hongmei Wang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jiangying XuanSchool of Basic Medical Sciences, Nanchang University, Nanchang 330006, China.ORCID 0000-0001-9599-181X
Yingxia LiuSchool of Basic Medical Sciences, Nanchang University, Nanchang 330006, China.
Xiaoping ZengSchool of Basic Medical Sciences, Nanchang University, Nanchang 330006, China.
Hongmei WangSchool of Basic Medical Sciences, Nanchang University, Nanchang 330006, China.
Nanchang University · CN

Funding

National Natural Science Foundation of China 82060526 and 81860540
6 · The paper itself

Abstract

MiRNAs (microRNAs) are the most abundant family of small noncoding RNAs in mammalian cells. Increasing evidence shows that miRNAs are crucial regulators of individual development and cell homeostasis by controlling various biological processes. Therefore, miRNA dysfunction can lead to human diseases, especially in cancers with high morbidity and mortality worldwide. MiRNAs play different roles in these processes. In recent years, studies have found that miR-424-5p is closely related to the occurrence, development, prognosis and treatment of tumors. This review discusses how miR-424-5p plays a role in different kinds of cancers from different stages of tumors, including its roles in (i) promoting or inhibiting tumorigenesis, (ii) regulating tumor development in the tumor microenvironment and (iii) participating in cancer chemotherapy. This review provides a deep discussion of the latest findings on miR-424-5p and its importance in cancer, as well as a mechanistic analysis of the role of miR-424-5p in various tissues through target gene verification and pathway analysis.

Indexed as

MicroRNAsNeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHumansMammalsTumor MicroenvironmentMicroRNAsMIRN424 microrna, humancancerchemotherapymiR-424-5ptumorigenesistumor microenvironment

Identifiers

PMID35409396
PMCPMC8999618
OpenAlexW4223528716

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.